Full-Time

Workflow Coordinator

Posted on 2/22/2025

Exact Sciences

Exact Sciences

5,001-10,000 employees

Biotechnology company for cancer detection and prevention

Compensation Overview

$50k - $81k/yr

+ Bonus + Company Stock

Junior

No H1B Sponsorship

Phoenix, AZ, USA

Category
Diagnostics & Laboratory Professionals
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's degree in a Chemistry, Biology, Clinical Laboratory Science, Medical Technology, or field related to the essential duties from an accredited college or university.
  • 1+ years’ experience in Clinical Laboratory testing and understanding in NGS workflow.
  • Demonstrate effective communication with all levels of staff.
  • Demonstrated ability to perform the essential duties of the position with or without accommodation.
  • Authorization to work in the United States without sponsorship.
Responsibilities
  • Manage and monitor the progression of all testing to ensure quality is maintained and turn-around-times are met.
  • Prioritize cases according to turn around time and STAT requests from clients.
  • Maintain accurate Pending log and Batch creation process.
  • Investigate and follow up on test failures, re-queue and TNP (Test not performed) samples.
  • Create and maintain accurate data on project reports to send to clients.
  • Assist in workflow, schedules, and bench coverage with the Laboratory Supervisors.
  • Assist the Biorepository team with shipments and returns as needed.
  • Proficient in using laboratory LIMS system.
  • Maintain working knowledge of basic processing flow for all laboratory steps/benches through ongoing continue education activities.
  • Apply strong communication skills.
  • Display excellent detail-oriented work.
  • Incorporate well organized work practices.
  • Uphold company mission and values through accountability, innovation, integrity, quality, and teamwork.
  • Support and comply with the company’s Quality Management System policies and procedures.
  • Maintain regular and reliable attendance.
  • Ability to act with an inclusion mindset and model these behaviors for the organization.
  • Ability to work designated schedule.
  • Ability to work nights and/or weekends.
  • Ability to work overtime, as needed.
  • Ability to work on a mobile device, tablet, or in front of a computer screen and/or perform typing for approximately 80% of a typical working day.
  • Ability to work on a computer and phone simultaneously.
  • Ability to work seated for approximately 90% of a typical working day. Ability to work standing for approximately 10% of a typical working day.
  • Some portions (10%) of daily assignments involve occupational risk, such as cuts, burns, exposure to toxic chemicals, injuries from falls, or back injury sustained with assisting in moving, lifting, or positioning equipment or materials.
  • Ability to grasp with both hands; pinch with thumb and forefinger; turn with hand/arm; reach above shoulder height.
  • Ability to comply with any applicable personal protective equipment requirements.
  • Ability to use near vision to view samples at close range.

Exact Sciences focuses on the early detection and prevention of cancer through advanced diagnostic tests. Their products are designed to identify cancer at its earliest stages, which helps healthcare providers make informed treatment decisions. The company operates globally, serving healthcare providers, patients, and research institutions in the medical diagnostics market. Unlike many competitors, Exact Sciences emphasizes a comprehensive approach that includes not only the development and sale of cancer screening tests but also support for patients and healthcare professionals. The main goal of Exact Sciences is to reduce the burden of cancer by providing effective diagnostic solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Madison, Wisconsin

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption enhances accuracy and efficiency of Exact Sciences' diagnostic tests.
  • Rise of telemedicine creates opportunities for Exact Sciences' at-home cancer screening solutions.
  • Advancements in liquid biopsy technology expand Exact Sciences' noninvasive screening capabilities.

What critics are saying

  • Increased competition from new entrants like Grail and Guardant Health in cancer diagnostics.
  • Potential reimbursement challenges for new tests like Cologuard Plus from insurance companies.
  • Rapid technological advancements may require significant R&D investment to stay competitive.

What makes Exact Sciences unique

  • Exact Sciences focuses on early cancer detection and prevention through innovative diagnostics.
  • The company launched Cologuard Plus, a next-gen noninvasive colorectal cancer screening test.
  • Partnership with Flatiron Health accelerates clinical evidence generation for MRD testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

Wellness Program

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Madison Startups
Mar 31st, 2025
Exact Sciences Launches Cologuard Plus Test

Exact Sciences has launched Cologuard Plus, a next-generation, noninvasive colorectal cancer screening text, the company announced today.

PR Newswire
Mar 18th, 2025
"Pick Up Your Poop" F Cancer'S New Campaign Encourages At-Home Colorectal Cancer Screening

Humorous PSA Highlights the Irony of Pet Owners' Willingness to Handle Dog Waste While Avoiding Their Own ScreeningCOSTA MESA, Calif., March 18, 2025 /PRNewswire/ -- Today, F Cancer, a non-profit dedicated to early cancer detection and prevention, is launching a Public Service Announcement (PSA) to encourage colorectal cancer screening for those 45+. Rolling out during Colon Cancer Awareness month, the campaign, titled "Pick up Your Poop," raises the point that dog owners readily pick up their animal's waste but remain squeamish about their own poop—in spite of the fact that taking a simple at home screening test can provide information that could help save their lives

Business Wire
Mar 12th, 2025
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

MADISON, Wis.-(BUSINESS WIRE)-Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition.

Hit Consultant
Feb 4th, 2025
Flatiron Health And Exact Sciences Partner To Accelerate Clinical Evidence Generation For Mrd Testing In Oncology

What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”

MarketBeat
Jan 19th, 2025
Retirement Wealth Solutions LLC Invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS)

Retirement Wealth Solutions LLC invests $327,000 in Exact Sciences Co. (NASDAQ:EXAS).

INACTIVE